Follow the Pundits

Tag: CASGEVY

Modern editorial illustration of CRISPR gene editing: a DNA helix morphs into a stock chart, with lab and Wall Street symbols representing breakthrough biotech potential and high volatility risk.

Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring

CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯

Read entire article

Tags: ARKG, ARKK, ARKK Fund, ARKK stocks, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, biotech jokes, Biotech Picks, Buy or sell CRSP, CASGEVY, Cathie Wood, Cathie Wood Stocks, CRISPR Therapeutics, CRSP, featured-hedge-funds, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Gene Editing, Growth Stocks, High Risk High Reward, hub-hedge, hub-insiders, Insider Purchases, risks buying crsp, Short Interest, why buy crsp